GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » Net Change in Cash

Bionano Genomics (MEX:BNGO) Net Change in Cash : MXN-258.7 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Bionano Genomics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Bionano Genomics's Net Change in Cash for the three months ended in Mar. 2025 was MXN-121.7 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-258.7 Mil.

Bionano Genomics Net Change in Cash Historical Data

The historical data trend for Bionano Genomics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Net Change in Cash Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only 420.48 -284.69 -371.99 218.24 -183.01

Bionano Genomics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.33 103.95 -248.87 7.91 -121.69

Bionano Genomics Net Change in Cash Calculation

Bionano Genomics's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1437.417+1539.964+-285.41+-0.146
=-183.0

Bionano Genomics's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-56.546+-287.765+222.81+-0.184
=-121.7

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-258.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » Net Change in Cash
Comparable Companies
MHUA HBIO LUCY POAI NXGL EKSO CBSC YBGJ RVP RSCF ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN
Traded in Other Exchanges
BNGO:USA
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Website
https://www.bionano.com
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.